|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Characterization of a critical role for CFTR chloride channels in cardioprotection against ischemia/ reperfusion injury显示文摘目的: 进一步描绘膀胱的纤维变性 transmembrane 传导力管理者(CFTR ) 的功能的角色在早、迟了(第二扇窗户) ischemic preconditioning (欧洲电脑生产厂商)- 并且 postconditioning (停靠港) 调停了对 ischemia/reperfusion (I/R ) 的 cardioprotection 损害。 | Sunny Yang XIANG Linda L YE Li-lu Marie DUAN Li-hui LIU Zhi-dong GE John A AUCHAMPACH Garrett J GROSS Dayue Darrel DUAN | 2011 | Acta Pharmacologica Sinica2011，32，6： | 9 |
| 2 | 钠-葡萄糖共转运蛋白-2抑制剂或胰高血糖素样肽-1受体激动剂治疗成人2型糖尿病:临床实践指南显示文摘临床问题对于存在不同心血管风险及肾脏结局的2型糖尿病患者,在原有生活方式干预和/或其他降糖药物的基础上加用钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂和胰高血糖素样肽1(GLP-1)受体激动剂的获益及风险是什么?现行做法几十年来,2型糖尿病的治疗决策都以控制血糖为主导。SGLT-2抑制剂和GLP-1受体激动剂在传统观念中常被用于二甲双胍治疗后血糖仍控制不佳的患者。目前这一现状已经发生了改变,这得益于多项临床研究结果。研究显示SGLT-2抑制剂和GLP-1受体激动剂拥有独立于药物降糖作用之外的对于动脉粥样硬化性心血管病(CVD)和慢性肾脏病(CKD)的获益。建议本指南阐述了针对不同风险分层的成人2型糖尿病患者使用SGLT-2抑制剂或GLP-1受体激动剂的建议。•伴有3种或更少的心血管风险因素且不存在CVD或CKD:不建议启动SGLT-2抑制剂或GLP-1受体激动剂治疗。(推荐等级:弱)•伴有3种以上心血管风险因素且不存在CVD或CKD:建议启动SGLT-2抑制剂治疗,不建议启动GLP-1受体激动剂治疗。(推荐等级:弱)•已经存在CVD或CKD:建议启动SGLT-2抑制剂治疗和GLP-1受体激动剂治疗。(推荐等级:弱)•已经存在CVD和CKD:建议启动SGLT-2抑制剂治疗(推荐等级:强)和GLP-1受体激动剂治疗。(推荐等级:弱)•对于那些想要进一步降低CVD和CKD结局风险的患者:推荐优先启用SGLT-2抑制剂治疗而非GLP-1受体激动剂治疗。(推荐等级:弱)这项指南是如何制订的一个由患者、临床医生和方法学家共同组成的国际小组提出了这些推荐意见。这些推荐意见基于可信度较高的指南的标准,并使用GRADE分级方法进行评估。该小组采用了息者个体化的观点。证据一项关于获益与风险的系统综述和网络meta分析(764项随机对照研究,包括421346例参与者)发现SGLT-2抑制剂和GLP-1受体激动剂可以降低总体死亡率、心肌梗死发生率、终末期肾病或肾衰竭的发生率(中等至高等质量的证据)。在不同的亚组中这些药物对卒中、因心力衰竭所致住院和其他主要不良事件有不同的影响。药物绝对获益的程度因患者个体风险的不同有很大的差异。(例如,对于接受了超过5年药物治疗的1000例患者,在最低风险人群中死亡人数减少了5人,在最高风险人群中死亡人数减少了48人)。一项关于预后的综述确认了14种风险预测模型,其中一种(RECODe)在证据总结中报告了大部分基线风险评估数据,小组利用该模型以支持风险分层的建议。考虑到患者的价值观及个体差异,指南推荐的支撑证据包括一项对已发表论文的系统综述、一项患者焦点小组研究、一项临床问题总结,以及一项指南调查。指南解读我们依据不同的CVD和CKD风险水平,综合考虑获益、风险和其他因素的平衡,以及每一个风险组别的实际问题,来对推荐意见进行分层。本指南强烈建议CVD和CKD患者使用SGLT-2抑制剂治疗,这说明专家组认为其具有显著的获益。而对于其他成人2型糖尿病患者,推荐等级较弱,这说明专家组想要在获益、风险及治疗花费上取得一个更好的平衡。临床医生通过该指南可以使用可靠的风险计算模型,如RECODe,来明确其患者的个体心血管和肾脏疾病风险。医患交互式总结临床证据和制订决策有助于患者知晓治疗选择,包括进行共同决策。2型糖尿病人群(全球患病率不断增长1-2)正面临着不断增加的心血管疾病、肾脏病和其他并发症的风险3。数十年来,2型糖尿病的管理始终以控制血糖及糖化血红蛋白(HbA1c)为治疗目标4-5,但是,最近的高质量随机对照研究已经对这种以血糖为中心的治疗模式发起了挑战。研究结果显示,强化血糖控制未必会降低大血管不良事件,它还可能带来不利影响监管机构现在要求新型糖尿病药物必须证明其具有心血管和肾脏获益才能获得批准。对两类新药--钠-葡萄糖共转运蛋白2(SGLT-2)抑制剂和胰高血糖素样肽1(GLP-1)受体激动剂(见框图1)的临床试验结果显示,在现有治疗方案(常规治疗)之上加用这些药物,对死亡、心肌梗死、卒中、心力衰竭和肾脏的结局(如进展为终末期肾病)都有获益8-12。 | Sheyu Li Per Olav Vandvik Lyubov Lytvyn Gordon H Guyatt Suetonia C Palmer Rene Rodriguez-Gutierrez Farid Foroutan Thomas Agoritsas Reed A C Siemieniuk Michael Walsh Lawrie Frere David J Tunnicliffe Evi V Nagler Veena Manja Bjφrn Olav Asvold Vivekanand Jha Mieke Vermandere Karim Gariani Qian Zhao Yan Ren Emma Jane Cartwright Patrick Gee Alan Wickes Linda Fems Robin Wright Ling Li Qiukui Hao Reem A Mustafa 无 郭鹤鸣(译) | 2021 | 英国医学杂志中文版2021，24，9： | 7 |
| 3 | Gamma irradiation of HIV-1显示文摘 | Richard A Smith Jesse Ingels John J Lochemes Joseph P Dutkowsky Linda L Pifer | 2001 | Journal of Orthopaedic Research2001，，5： | 2 |
| 4 | Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders显示文摘 | E Joanna Baxter Linda M Scott Peter J Campbell Clare East Nasios Fourouclas Soheila Swanton George S Vassiliou Anthony J Bench Elaine M Boyd Natasha Curtin Mike A Scott Wendy N Erber Anthony R Green | 2005 | The Lancet . 2005 (9464)2005，，： | 2 |
| 5 | Non-steroidal anti-inflammatory drugs and risk of neoplastic progression in Barrett’s oesophagus: a prospective study显示文摘 | Thomas L Vaughan Linda M Dong Patricia L Blount Kamran Ayub Robert D Odze Carissa A Sanchez Peter S Rabinovitch Brian J Reid | 2005 | Lancet Oncology2005，，12： | 2 |
| 6 | Factors associated with 5-year survival of combined hepatocellular and cholangiocarcinoma显示文摘BACKGROUND Combined hepatocellular and cholangiocarcinoma(HCC/CC)is a rare primary hepatic malignancy which carries a poor prognosis due to its aggressive nature.Few centers have enough cases to draw definitive conclusions and there is limited understanding of prognosis.Given the rarity of HCC/CC,an analysis of large national cancer database was needed to obtain larger number of HCC/CC cases.AIM To identify associated factors for 5-year survival of HCC/CC.METHODS We conducted a retrospective study of The Surveillance,Epidemiology,and End Results(SEER)database obtained from SEER*Stat 8.3.6 software.Previously defined histology code 8180 for the International Classification of Disease for Oncology,3rd edition was used to identify HCC/CC cases from 2004 to 2015.We collected demographics,American Joint Committee on Cancer(AJCC)stage,treatment,tumor size,and survival data.These data were converted to categorical variables.The Shapiro-Wilk normality test was used to assess normal distribution.Mann-Whitney U test was used to compare continuous variables without normal distribution,and t-test was used to compare continuous variables with a normal distribution.The Kaplan-Meier survival curve analyzed 5-year survival.Univariate and multivariate logistic regression model was used to analyze factors associated with 5-year survival.Multivariate Cox proportional hazard regression was done on 5-year survival.We defined P<0.05 was statistically significant.RESULTS We identified 497 patients with the following characteristics:Mean age 62.4 years(SD:11.3),149(30.0%)were female,racial distribution was:276(55.5%)white,53(10.7%)black,84(16.9%)Asian and Pacific Islander(API),77(15.5%)Hispanic,and 7(1.4%)others or unknown.Stage I/II disease occurred in 41.5%and tumor size<50 mm was seen in 35.6%of patients.Twenty-four(4.8%)received locoregional therapy(LRT),119(23.9%)underwent resection,and 50(10.1%)underwent liver transplantation.The overall median survival was 6 mo[Interquartile range(IQR):1-22].After multivariate logistic regression,tumor size<50 mm[Odds ratios(OR):2.415,P=0.05],resection(OR:12.849,P<0.01),and transplant(OR:27.129,P<0.01)showed significance for 5-year survival.Age>60,sex,race,AJCC stages,metastasis,and LRT were not significant.However,API vs white showed significant OR of 2.793(CI:1.120-6.967).Cox proportional hazard regression showed AJCC stages,tumor size<50 mm,LRT,resection,and transplant showed significant hazard ratio.CONCLUSION HCC/CC patients with tumor size<50 mm,resection,and transplant were associated with an increase in 5-year survival.API showed advantageous OR and hazard ratios over white,black. | Tomoki Sempokuya Eric A Wien Robert J Pattison Jihyun Ma Linda L Wong | 2020 | World Journal of Hepatology2020，12，11： | 2 |
| 7 | Doing competencies well:best practics in competency modeling显示文摘 | Michael A Campion Alexis A Fink Brian J Ruggeberg Linda Carr Geneva M Phillips Ronald B Odman | 2011 | Personnel Psychology2011，，22： | 1 |
| 8 | Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer显示文摘 | Connie PM Duong Jennifer A Westwood Linda J Berry Phillip K Darcy Michael H Kershaw | 2011 | Immunotherapy2011，，1： | 1 |
| 9 | Liquefaction of Autographa californica Nucleopolyhedrovirus-Infected Insects Is Dependent on the Integrity of Virus-Encoded Chitinase and Cathepsin Genes显示文摘 | Rachael E Hawtin Tamara Zarkowska Kevin Arnold Carole J Thomas Graham W Gooday Linda A King John A Kuzio Robert D Possee | 1997 | Virology1997，，： | 1 |
| 10 | Market Reac- tions to the Disclosure of Internal Control Weaknesses and to the Characteristics of Those Weaknesses Under Section 302 of the Sarbanes - Oxley Act of 2002 显示文摘 | Hammersley J S M A Linda C Shakespeare | 2008 | Review of Account- ing Studies2008，13，1： | 1 |
| 11 | Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial显示文摘 | George L Bakris Pantelis A Sarafidis Matthew R Weir Bj?rn Dahl?f Bertram Pitt Kenneth Jamerson Eric J Velazquez Linda Staikos-Byrne Roxzana Y Kelly Victor Shi Yann-Tong Chiang Michael A Weber | 2010 | The Lancet2010，，9721： | 1 |
| 12 | Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction 显示文摘 | JAMES L JANUZZI JR MD SHAFIQ U REHMAN M D ASIM A MOHAMMED M D ANJU BHARDWAJ M D LINDA BARAJAS R N JUSTINE BARAJAS HAN-NA KIM M D MPH AARON L BAGGISH M D RORY B WEINER M D ANNABEL CHEN-TOURNOUX MD JANE E MARSHALL RDCS STEPHANIE A MOORE M D WILLIAM D CARLSON M D GREGORY D LEWIS M D JORDAN SHIN M D DOROTHY SULLIVAN ANP KIMBERLY PARKS D O THOMAS J WANG M D SHAWN A GREGORY M D SHANMUGAM UTHAMALINGAM M D MARC J SEMIGRAN M D | 2011 | J Am Coll Cardiol2011，58，18： | 1 |
| 13 | Detection and quantification of microcystins (cyanobacterial hepatotoxins) with recombinant antibody fragments isolated from a naive human phage display library显示文摘 | McElhiney J Lawton Linda A Porter Andrew JR | 2000 | FEMS Microbiol Letters2000，193，1： | 1 |
| 14 | Hormesis: U-shaped dose responses and their centrality in toxicology 显示文摘 | Calabrese E J Linda A B | 2001 | Trends in Pharmacological Sciences2001，22，6： | 1 |
| 15 | Direct in vivo visualization of intravascular destruction of microbubbles by ultrasound and its effects on tissue显示文摘 | Skyba D M Price R J Linda A Z | 1998 | Circulation1998，98，： | 1 |
| 16 | The interplay between climate change, forests, and disturbances显示文摘 | VIRGINIA H D LINDA A J STEVE M | 2000 | Science of the Total Environment2000，262，： | 1 |
| 17 | Three-dimensional aromaticity in highly symmetric hydrogen clusters显示文摘 | Cook M J Katritzky A R Linda P | 1974 | J Heterocyclic Chem1974，，14： | 1 |
| 18 | U-shaped dose-responses in biology,toxicology,and public显示文摘 | EDWARD J C LINDA A B | 2001 | Annu Rec Public Health2001，22，： | 1 |
| 19 | Articular cartilage and changes in Arthritts: cell biology of osteoarthritis 显示文摘 | Linda J Sandell Thomas A | 2001 | Arthritis Res2001，3，2： | 1 |
| 20 | Global carbon isotopic events associated with mass extinction and glaciation in the late Ordovician显示文摘 | James D Marshall Patrick J Brenchley Paul Mason George A Wolff Ricardo A Astini Linda Hints T?nu Meidla | 1997 | Palaeogeography Palaeoclimatology Palaeoecology1997，，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员